Review



egfr monoclonal antibody msigg  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech egfr monoclonal antibody msigg
    Characterization of gefitinib-resistant PC9GR cells and the role of CEMIP in gefitinib resistance. A, The scheme of induction of gefitinib resistance from PC9 cells. B, Cell viability of PC9 and PC9GR after treating gefitinib in 24 h, 48 h and 72 h. IC 50 values and RI of gefitinib (PC9GR/PC9) as shown below respectively. The resistant indexs of 24 h, 48 h and 72 h were 224.47, 677.39 and 952.14 respectively. C, PI/DAPI staining to assess cell deaths in PC9 and PC9GR cells with (lower panel) or without (upper panel) gefitinib treatment for 24 h, concentration of gefitinib was 0.1 μM for PC9, and 10 μM for PC9GR respectively. Magnification 100 × . D, FCM assay of cell apoptosis and viability in PC9 and PC9GR cells when treated with gefitinib for 48 h, concentration of gefitinib was 0.02 μM for PC9, and 10 μM for PC9GR respectively. E, The expression of <t>p-EGFR</t> and EGFR in PC9 and PC9GR cells under the treatment of Gefitinib (0.02 μM vs 10 μM) of 48 h. F, The binding effects of gefitinib to EGFR in PC9 and PC9GR cells, which were detected by CETSA assays. G, The expression of CEMIP in PC9 and PC9GR cells. H, The corelationship analysis between IC 50 value of gefitinib and the expression of CEMIP in the lung cancer cell lines, data were acquired from GDSC2 database. Results of Pearson correlation analysis were indicated in the upper panel of each chart, respectively. I, The validation of mRNA expression of CEMIP in PC9 cells with over-expressing CEMIP or PC9GR cells with interference of CEMIP expression. J, The validation of protein expression of CEMIP after transfecting with LV-encapsulated overexpressing or interference of CEMIP. K, Cell viability assays to determine gefitinib IC 50 in PC9 and PC9GR cells after transfecting with LV-encapsulated overexpressing or interference of CEMIP. Results ( n = 3) displayed as Mean ± SD, *, ** and #, ## presented P value < 0.05 and 0.01, respectively.
    Egfr Monoclonal Antibody Msigg, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 205 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr monoclonal antibody msigg/product/Proteintech
    Average 96 stars, based on 205 article reviews
    egfr monoclonal antibody msigg - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC"

    Article Title: CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC

    Journal: BBA Advances

    doi: 10.1016/j.bbadva.2025.100176

    Characterization of gefitinib-resistant PC9GR cells and the role of CEMIP in gefitinib resistance. A, The scheme of induction of gefitinib resistance from PC9 cells. B, Cell viability of PC9 and PC9GR after treating gefitinib in 24 h, 48 h and 72 h. IC 50 values and RI of gefitinib (PC9GR/PC9) as shown below respectively. The resistant indexs of 24 h, 48 h and 72 h were 224.47, 677.39 and 952.14 respectively. C, PI/DAPI staining to assess cell deaths in PC9 and PC9GR cells with (lower panel) or without (upper panel) gefitinib treatment for 24 h, concentration of gefitinib was 0.1 μM for PC9, and 10 μM for PC9GR respectively. Magnification 100 × . D, FCM assay of cell apoptosis and viability in PC9 and PC9GR cells when treated with gefitinib for 48 h, concentration of gefitinib was 0.02 μM for PC9, and 10 μM for PC9GR respectively. E, The expression of p-EGFR and EGFR in PC9 and PC9GR cells under the treatment of Gefitinib (0.02 μM vs 10 μM) of 48 h. F, The binding effects of gefitinib to EGFR in PC9 and PC9GR cells, which were detected by CETSA assays. G, The expression of CEMIP in PC9 and PC9GR cells. H, The corelationship analysis between IC 50 value of gefitinib and the expression of CEMIP in the lung cancer cell lines, data were acquired from GDSC2 database. Results of Pearson correlation analysis were indicated in the upper panel of each chart, respectively. I, The validation of mRNA expression of CEMIP in PC9 cells with over-expressing CEMIP or PC9GR cells with interference of CEMIP expression. J, The validation of protein expression of CEMIP after transfecting with LV-encapsulated overexpressing or interference of CEMIP. K, Cell viability assays to determine gefitinib IC 50 in PC9 and PC9GR cells after transfecting with LV-encapsulated overexpressing or interference of CEMIP. Results ( n = 3) displayed as Mean ± SD, *, ** and #, ## presented P value < 0.05 and 0.01, respectively.
    Figure Legend Snippet: Characterization of gefitinib-resistant PC9GR cells and the role of CEMIP in gefitinib resistance. A, The scheme of induction of gefitinib resistance from PC9 cells. B, Cell viability of PC9 and PC9GR after treating gefitinib in 24 h, 48 h and 72 h. IC 50 values and RI of gefitinib (PC9GR/PC9) as shown below respectively. The resistant indexs of 24 h, 48 h and 72 h were 224.47, 677.39 and 952.14 respectively. C, PI/DAPI staining to assess cell deaths in PC9 and PC9GR cells with (lower panel) or without (upper panel) gefitinib treatment for 24 h, concentration of gefitinib was 0.1 μM for PC9, and 10 μM for PC9GR respectively. Magnification 100 × . D, FCM assay of cell apoptosis and viability in PC9 and PC9GR cells when treated with gefitinib for 48 h, concentration of gefitinib was 0.02 μM for PC9, and 10 μM for PC9GR respectively. E, The expression of p-EGFR and EGFR in PC9 and PC9GR cells under the treatment of Gefitinib (0.02 μM vs 10 μM) of 48 h. F, The binding effects of gefitinib to EGFR in PC9 and PC9GR cells, which were detected by CETSA assays. G, The expression of CEMIP in PC9 and PC9GR cells. H, The corelationship analysis between IC 50 value of gefitinib and the expression of CEMIP in the lung cancer cell lines, data were acquired from GDSC2 database. Results of Pearson correlation analysis were indicated in the upper panel of each chart, respectively. I, The validation of mRNA expression of CEMIP in PC9 cells with over-expressing CEMIP or PC9GR cells with interference of CEMIP expression. J, The validation of protein expression of CEMIP after transfecting with LV-encapsulated overexpressing or interference of CEMIP. K, Cell viability assays to determine gefitinib IC 50 in PC9 and PC9GR cells after transfecting with LV-encapsulated overexpressing or interference of CEMIP. Results ( n = 3) displayed as Mean ± SD, *, ** and #, ## presented P value < 0.05 and 0.01, respectively.

    Techniques Used: Staining, Concentration Assay, Expressing, Binding Assay, Biomarker Discovery



    Similar Products

    egfr monoclonal antibody msigg  (Proteintech)
    96
    Proteintech egfr monoclonal antibody msigg
    Characterization of gefitinib-resistant PC9GR cells and the role of CEMIP in gefitinib resistance. A, The scheme of induction of gefitinib resistance from PC9 cells. B, Cell viability of PC9 and PC9GR after treating gefitinib in 24 h, 48 h and 72 h. IC 50 values and RI of gefitinib (PC9GR/PC9) as shown below respectively. The resistant indexs of 24 h, 48 h and 72 h were 224.47, 677.39 and 952.14 respectively. C, PI/DAPI staining to assess cell deaths in PC9 and PC9GR cells with (lower panel) or without (upper panel) gefitinib treatment for 24 h, concentration of gefitinib was 0.1 μM for PC9, and 10 μM for PC9GR respectively. Magnification 100 × . D, FCM assay of cell apoptosis and viability in PC9 and PC9GR cells when treated with gefitinib for 48 h, concentration of gefitinib was 0.02 μM for PC9, and 10 μM for PC9GR respectively. E, The expression of <t>p-EGFR</t> and EGFR in PC9 and PC9GR cells under the treatment of Gefitinib (0.02 μM vs 10 μM) of 48 h. F, The binding effects of gefitinib to EGFR in PC9 and PC9GR cells, which were detected by CETSA assays. G, The expression of CEMIP in PC9 and PC9GR cells. H, The corelationship analysis between IC 50 value of gefitinib and the expression of CEMIP in the lung cancer cell lines, data were acquired from GDSC2 database. Results of Pearson correlation analysis were indicated in the upper panel of each chart, respectively. I, The validation of mRNA expression of CEMIP in PC9 cells with over-expressing CEMIP or PC9GR cells with interference of CEMIP expression. J, The validation of protein expression of CEMIP after transfecting with LV-encapsulated overexpressing or interference of CEMIP. K, Cell viability assays to determine gefitinib IC 50 in PC9 and PC9GR cells after transfecting with LV-encapsulated overexpressing or interference of CEMIP. Results ( n = 3) displayed as Mean ± SD, *, ** and #, ## presented P value < 0.05 and 0.01, respectively.
    Egfr Monoclonal Antibody Msigg, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr monoclonal antibody msigg/product/Proteintech
    Average 96 stars, based on 1 article reviews
    egfr monoclonal antibody msigg - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Characterization of gefitinib-resistant PC9GR cells and the role of CEMIP in gefitinib resistance. A, The scheme of induction of gefitinib resistance from PC9 cells. B, Cell viability of PC9 and PC9GR after treating gefitinib in 24 h, 48 h and 72 h. IC 50 values and RI of gefitinib (PC9GR/PC9) as shown below respectively. The resistant indexs of 24 h, 48 h and 72 h were 224.47, 677.39 and 952.14 respectively. C, PI/DAPI staining to assess cell deaths in PC9 and PC9GR cells with (lower panel) or without (upper panel) gefitinib treatment for 24 h, concentration of gefitinib was 0.1 μM for PC9, and 10 μM for PC9GR respectively. Magnification 100 × . D, FCM assay of cell apoptosis and viability in PC9 and PC9GR cells when treated with gefitinib for 48 h, concentration of gefitinib was 0.02 μM for PC9, and 10 μM for PC9GR respectively. E, The expression of p-EGFR and EGFR in PC9 and PC9GR cells under the treatment of Gefitinib (0.02 μM vs 10 μM) of 48 h. F, The binding effects of gefitinib to EGFR in PC9 and PC9GR cells, which were detected by CETSA assays. G, The expression of CEMIP in PC9 and PC9GR cells. H, The corelationship analysis between IC 50 value of gefitinib and the expression of CEMIP in the lung cancer cell lines, data were acquired from GDSC2 database. Results of Pearson correlation analysis were indicated in the upper panel of each chart, respectively. I, The validation of mRNA expression of CEMIP in PC9 cells with over-expressing CEMIP or PC9GR cells with interference of CEMIP expression. J, The validation of protein expression of CEMIP after transfecting with LV-encapsulated overexpressing or interference of CEMIP. K, Cell viability assays to determine gefitinib IC 50 in PC9 and PC9GR cells after transfecting with LV-encapsulated overexpressing or interference of CEMIP. Results ( n = 3) displayed as Mean ± SD, *, ** and #, ## presented P value < 0.05 and 0.01, respectively.

    Journal: BBA Advances

    Article Title: CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC

    doi: 10.1016/j.bbadva.2025.100176

    Figure Lengend Snippet: Characterization of gefitinib-resistant PC9GR cells and the role of CEMIP in gefitinib resistance. A, The scheme of induction of gefitinib resistance from PC9 cells. B, Cell viability of PC9 and PC9GR after treating gefitinib in 24 h, 48 h and 72 h. IC 50 values and RI of gefitinib (PC9GR/PC9) as shown below respectively. The resistant indexs of 24 h, 48 h and 72 h were 224.47, 677.39 and 952.14 respectively. C, PI/DAPI staining to assess cell deaths in PC9 and PC9GR cells with (lower panel) or without (upper panel) gefitinib treatment for 24 h, concentration of gefitinib was 0.1 μM for PC9, and 10 μM for PC9GR respectively. Magnification 100 × . D, FCM assay of cell apoptosis and viability in PC9 and PC9GR cells when treated with gefitinib for 48 h, concentration of gefitinib was 0.02 μM for PC9, and 10 μM for PC9GR respectively. E, The expression of p-EGFR and EGFR in PC9 and PC9GR cells under the treatment of Gefitinib (0.02 μM vs 10 μM) of 48 h. F, The binding effects of gefitinib to EGFR in PC9 and PC9GR cells, which were detected by CETSA assays. G, The expression of CEMIP in PC9 and PC9GR cells. H, The corelationship analysis between IC 50 value of gefitinib and the expression of CEMIP in the lung cancer cell lines, data were acquired from GDSC2 database. Results of Pearson correlation analysis were indicated in the upper panel of each chart, respectively. I, The validation of mRNA expression of CEMIP in PC9 cells with over-expressing CEMIP or PC9GR cells with interference of CEMIP expression. J, The validation of protein expression of CEMIP after transfecting with LV-encapsulated overexpressing or interference of CEMIP. K, Cell viability assays to determine gefitinib IC 50 in PC9 and PC9GR cells after transfecting with LV-encapsulated overexpressing or interference of CEMIP. Results ( n = 3) displayed as Mean ± SD, *, ** and #, ## presented P value < 0.05 and 0.01, respectively.

    Article Snippet: EGFR Monoclonal antibody(MsIgG) , ProteinTech Co. (66455–1-Ig).

    Techniques: Staining, Concentration Assay, Expressing, Binding Assay, Biomarker Discovery